Surfactant Replacement Therapy for Respiratory Distress Syndrome

ABSTRACT. Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight immature infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. The statement summarizes the indications for surfactant replacement therapy. Because respiratory insufficiency may be a component of multorgan dysfunction in sick infants, surfactant should be administered only at institutions with qualified personnel and facilities for the comprehensive care of sick infants.

Exogenous surfactant replacement has been established as an appropriate preventive and treatment therapy for prematurity-related surfactant deficiency. Surfactant therapy also may be indicated for more mature infants with primary pulmonary hypertension or meconium aspiration syndrome. Single and multicenter randomized controlled trials using synthetic, modified animal, purified animal, and human surfactants have shown that the use of surfactant replacement in preventive or treatment modes has been safe and efficacious.1–18 Reduced mortality rates and improved short-term respiratory status for preterm infants with surfactant-deficiency respiratory distress have been confirmed. However, coexistent morbidity, such as necrotizing enterocolitis, nosocomial infections, patent ductus arteriosus, intraventricular hemorrhage, and chronic lung disease, appear primarily unaffected. Reports of long-term outcome for infants enrolled in the randomized surfactant trials and evaluated at 1 to 2 years of age have shown neither beneficial nor adverse effects of surfactant use on growth and/or neurodevelopmental parameters.19–26

Current studies continue to address refinements in surfactant use that may optimize its effectiveness. New products, timing, dosage, methods of administration, and modification for particular gestational age groups are among the issues that may improve the effect of surfactants. Two surfactants, one synthetic and the other modified bovine, have been licensed and are available commercially in the United States.

Universal availability of these products raises the concern that surfactants may be used to address the respiratory component of multisystem disorders that affect high-risk, low birth weight infants when other diseases cannot be addressed appropriately. This is a critical issue because the target population for surfactant therapy is primarily the high-risk, low birth weight infants who may have multisystem disorders that are not affected beneficially by treatment with surfactants. Caring for these infants in nurseries without the full range of capabilities required may affect the overall outcome adversely.27,28 As systems of neonatal health care adapt to modified patterns of disease in low birth weight infants, the following recommendations should be incorporated.

RECOMMENDATIONS

1. Surfactant replacement therapy should be directed by physicians qualified and trained in its use and administration. Qualifications should include experience in management of the respiratory care of low birth weight infants, particularly those on mechanical ventilation.

2. Nursing and respiratory therapy personnel experienced in the management of low birth weight infants, including mechanical ventilation, should be available within the unit at the bedside when surfactant therapy is administered.

3. Equipment necessary for managing and monitoring the condition of low birth weight infants, including that needed for mechanical ventilation, should be available on-site when surfactant therapy is administered. Radiology and laboratory support to manage a broad range of needs of these infants should be available.

4. More important, surfactant therapy should be used only in institutions in which facilities and personnel are available for the management of multisystem disorders and low birth weight infants.

5. An institutionally approved surfactant therapy protocol, which is a mandatory component of the quality assurance program for neonates, should exist.

6. In the institutions not satisfying recommendations 2 through 5, and when timely transfer to an appropriate institution cannot be achieved, surfactant therapy may be given, but only by a physician skilled in endotracheal intubation. Under these circumstances, consultation with a subspecialty center should be obtained. Infants should be transferred from such institutions if appropriate and when feasible to a center with appropriate facilities and staff trained to care for multisystem morbidity in low birth weight infants.

The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
Surfactant Replacement Therapy for Respiratory Distress Syndrome
Committee on Fetus and Newborn
Pediatrics 1999;103;684
DOI: 10.1542/peds.103.3.684

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/103/3/684

References
This article cites 24 articles, 10 of which you can access for free at:
http://pediatrics.aappublications.org/content/103/3/684.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Fetus/Newborn Infant
http://classic.pediatrics.aappublications.org/cgi/collection/fetus:newborn_infant_sub
Pulmonology
http://classic.pediatrics.aappublications.org/cgi/collection/pulmonology_sub
Respiratory Tract
http://classic.pediatrics.aappublications.org/cgi/collection/respiratory_tract_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 1999 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .
Surfactant Replacement Therapy for Respiratory Distress Syndrome
Committee on Fetus and Newborn

Pediatrics 1999;103:684
DOI: 10.1542/peds.103.3.684

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/103/3/684